-
Je něco špatně v tomto záznamu ?
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
L. Antunes, C. Mazagatos, I. Martínez-Baz, V. Gomez, ML. Borg, G. Petrović, R. Duffy, FE. Dufrasne, R. Dürrwald, M. Lazar, L. Jancoriene, B. Oroszi, P. Husa, J. Howard, A. Melo, F. Pozo, G. Pérez-Gimeno, J. Castilla, A. Machado, A. Džiugytė, S....
Jazyk angličtina Země Švédsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1996
Free Medical Journals
od 1995
Freely Accessible Science Journals
od 1995-09-01
PubMed Central
od 2016
Europe PubMed Central
od 2016
Open Access Digital Library
od 1996-01-01
Open Access Digital Library
od 2016-01-01
Medline Complete (EBSCOhost)
od 2010-07-01
ROAD: Directory of Open Access Scholarly Resources
od 1995
- MeSH
- COVID-19 * prevence a kontrola MeSH
- hospitalizace MeSH
- lidé MeSH
- messenger RNA MeSH
- SARS-CoV-2 genetika MeSH
- studie případů a kontrol MeSH
- vakcíny proti COVID-19 * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.
Cantacuzino National Military Medical Institute for Research and Development Bucharest Romania
CIBER Epidemiología y Salud Pública Madrid Spain
Consortium for Biomedical Research in Epidemiology and Public Health Madrid Spain
Croatian Institute of Public Health Zagreb Croatia
Department for Infectious Disease Epidemiology Robert Koch Institute Berlin Germany
Department of Infectious Diseases Lithuanian University of Health Sciences Kaunas Lithuania
Epidemiology Department National Health Institute Doutor Ricardo Jorge Lisbon Portugal
European Centre for Disease Prevention and Control Stockholm Sweden
Health Service Executive Health Protection Surveillance Centre Dublin Ireland
Infectious Disease Prevention and Control Unit Health Promotion and Disease Prevention Msida Malta
Infectious Diseases Department National Health Institute Doutor Ricardo Jorge Lisbon Portugal
Instituto de Salud Pública de Navarra IdiSNA Pamplona Spain
National Centre for Epidemiology Institute of Health Carlos 3 Madrid Spain
National Centre for Microbiology Institute of Health Carlos 3 Madrid Spain
National Influenza Centre Laboratory of Viral Diseases Sciensano Brussels Belgium
National Reference Centre for Influenza Robert Koch Institute Berlin Germany
Service Epidemiology of Infectious Diseases Sciensano Brussels Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007705
- 003
- CZ-PrNML
- 005
- 20240423160210.0
- 007
- ta
- 008
- 240412s2024 sw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2807/1560-7917.ES.2024.29.3.2300708 $2 doi
- 035 __
- $a (PubMed)38240061
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Antunes, Liliana $u Epiconcept, Paris, France
- 245 10
- $a Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023 / $c L. Antunes, C. Mazagatos, I. Martínez-Baz, V. Gomez, ML. Borg, G. Petrović, R. Duffy, FE. Dufrasne, R. Dürrwald, M. Lazar, L. Jancoriene, B. Oroszi, P. Husa, J. Howard, A. Melo, F. Pozo, G. Pérez-Gimeno, J. Castilla, A. Machado, A. Džiugytė, S. Karabuva, M. Fitzgerald, S. Fierens, K. Tolksdorf, SO. Popovici, A. Mickienė, G. Túri, L. Součková, N. Nicolay, AM. Rose, European Hospital Vaccine Effectiveness Group
- 520 9_
- $a We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a vakcíny proti COVID-19 $7 D000086663
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 12
- $a COVID-19 $x prevence a kontrola $7 D000086382
- 650 _2
- $a SARS-CoV-2 $x genetika $7 D000086402
- 650 _2
- $a hospitalizace $7 D006760
- 650 _2
- $a messenger RNA $7 D012333
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mazagatos, Clara $u National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- 700 1_
- $a Martínez-Baz, Iván $u Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain $u CIBER Epidemiología y Salud Pública, Madrid, Spain
- 700 1_
- $a Gomez, Verónica $u Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal
- 700 1_
- $a Borg, Maria-Louise $u Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta
- 700 1_
- $a Petrović, Goranka $u Croatian Institute of Public Health, Zagreb, Croatia
- 700 1_
- $a Duffy, Róisín $u Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland
- 700 1_
- $a Dufrasne, François E $u National Influenza Centre Laboratory of Viral Diseases, Sciensano, Brussels, Belgium
- 700 1_
- $a Dürrwald, Ralf $u National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany
- 700 1_
- $a Lazar, Mihaela $u Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania
- 700 1_
- $a Jancoriene, Ligita $u Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Lithuania
- 700 1_
- $a Oroszi, Beatrix $u National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Husa, Petr $u University Hospital Brno, Masaryk University, Brno, Czechia
- 700 1_
- $a Howard, Jennifer $u Epiconcept, Paris, France
- 700 1_
- $a Melo, Aryse $u Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal
- 700 1_
- $a Pozo, Francisco $u National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain
- 700 1_
- $a Pérez-Gimeno, Gloria $u National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- 700 1_
- $a Castilla, Jesús $u Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain $u CIBER Epidemiología y Salud Pública, Madrid, Spain
- 700 1_
- $a Machado, Ausenda $u Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal
- 700 1_
- $a Džiugytė, Aušra $u Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta
- 700 1_
- $a Karabuva, Svjetlana $u University Hospital Centre Split, Split, Croatia
- 700 1_
- $a Fitzgerald, Margaret $u Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland
- 700 1_
- $a Fierens, Sébastien $u Service Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium
- 700 1_
- $a Tolksdorf, Kristin $u Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
- 700 1_
- $a Popovici, Silvia-Odette $u National Institute of Public Health, National Centre for Communicable Diseases Surveillance and Control, Bucharest, Romania
- 700 1_
- $a Mickienė, Auksė $u Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Túri, Gergő $u National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Součková, Lenka $u University Hospital Brno, Masaryk University, Brno, Czechia
- 700 1_
- $a Nicolay, Nathalie $u European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- 700 1_
- $a Rose, Angela Mc $u Epiconcept, Paris, France
- 710 2_
- $a European Hospital Vaccine Effectiveness Group
- 773 0_
- $w MED00174364 $t Euro surveillance $x 1560-7917 $g Roč. 29, č. 3 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38240061 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160206 $b ABA008
- 999 __
- $a ok $b bmc $g 2081596 $s 1217472
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 29 $c 3 $e - $i 1560-7917 $m Euro surveillance $n Euro Surveill $x MED00174364
- LZP __
- $a Pubmed-20240412
